Access to Medicines Tracker

Each quarter, we monitor the progress of our generic partners in developing, filing and selling MPP’s licensed medicines, in countries where access could not have been possible without our work.

The Medicines Patent Pool (MPP) has signed agreements with ten patent holders for 13 HIV antiretrovirals, one HIV technology platform, a tuberculosis treatment and three hepatitis C direct-acting antivirals. 22 generic manufacturers and product developers have now signed MPP sublicensing agreements.

Overview of all licensing and sublicensing agreements

Generic competition is making a difference in fostering lower prices and improving treatment coverage. Generic partners have distributed 38.75 million patient-years of HIV and hepatitis C products, saving international procurers USD 1.66 billion (January 2012-June 2020).

Slide decks highlighting progress of MPP’s generic partners in developing, manufacturing and supplying MPP-licensed medicines, are available for:

(Last update: October 2020 – data as of June 2020)

*[WHO-PQ] Prequalification from the World Health Organization | **[USFDA] U.S. Food and Drug Administration | ***[ERP] Expert Review Panel led by the Global Fund. Temporary approval through an ERP is permitted where WHO-PQ or USFDA approval are not yet available. This does not apply to products under licences with Gilead Sciences (those licences do not accept ERP).

Interactive map:
– Patent and licensing status: last updated on 12 October 2020;
– Product availability data from MPP sublicensees: last updated on 20 January 2021 (data as of 30 September 2020).

Last update of the interactive table: 30 September 2020 (data as of 30 June 2020)

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
MPP Logo

Subscribe to our Newsletter

Founded & funded by

Unitaid Logo

Other funders

This website uses cookies to ensure you get the best experience on our website. Learn More